James Hugh Segars

Dr. James Hugh Segars

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
ECEden R. Cardozo
Eden R. Cardozo
ACAndrew D. Clark
Andrew D. Clark
NBNicole K. Banks
Nicole K. Banks
MHMelinda B. Henne
Melinda B. Henne
BSBarbara J. Stegmann
Barbara J. Stegmann
JSJames Hugh Segars
James Hugh Segars

1 February 2009 in Fertility and Sterility
Verified
Journal Article
Closed access
SMSomjate Manipalviratn
Somjate Manipalviratn
ADAlan DeCherney
Alan DeCherney
JSJames Hugh Segars
James Hugh Segars

3 January 2014 in Seminars in Reproductive Medicine
Verified
Journal Article
Closed access
PDF file
ISIdo Sirota
Ido Sirota
SZShvetha M. Zarek
Shvetha M. Zarek
JSJames Hugh Segars
James Hugh Segars
Although an altered vaginal microbiota has been demonstrated to affect parturition, its role in assisted reproductive technologies is uncertain. Nevertheless, the effect of known pathogens such as Mycoplasma tuberculosis, Chlamydia trachomatis, and Neisseria gonorrhoeae is clear, causing subclinical changes thought to be risk factors in subfertility. The Human Microbiome Project (HMP) has allowed for metagenomic studies to aid in characterizing normal vaginal flora. Recent findings from the HMP demonstrate that many different species of Lactobacillus are present in the vaginal tract, with a few that predominate. Studies that characterize the vaginal microbiome in assisted reproductive technology support the hypothesis that colonizing the transfer-catheter tip with Lactobacillus crispatus at the time of embryo transfer may increase the rates of implantation and live birth rate while decreasing the rate of infection. In addition, there is some evidence that a progesterone-resistant endometrium might increase the risk of an abnormal vaginal microbiome. The views expressed in this article are those of the authors and do not reflect the official policy or position of the U.S. Government.

29 September 2013 in Human Reproduction Update
Verified
Journal Article
Open access
PDF file
RTReshef Tal
Reshef Tal
JSJames Hugh Segars
James Hugh Segars
It is well established that tumors are dependent on angiogenesis for their growth and survival. Although uterine fibroids are known to be benign tumors with reduced vascularization, recent work demonstrates that the vasculature of fibroids is grossly and microscopically abnormal. Accumulating evidence suggests that angiogenic growth factor dysregulation may be implicated in these vascular and other features of fibroid pathophysiology. Literature searches were performed in PubMed and Google Scholar for articles with content related to angiogenic growth factors and myometrium/leiomyoma. The findings are hereby reviewed and discussed. Multiple growth factors involved in angiogenesis are differentially expressed in leiomyoma compared with myometrium. These include epidermal growth factor (EGF), heparin-binding-EGF, vascular endothelial growth factor, basic fibroblast growth factor, platelet-derived growth factor, transforming growth factor-β and adrenomedullin. An important paradox is that although leiomyoma tissues are hypoxic, leiomyoma feature down-regulation of key molecular regulators of the hypoxia response. Furthermore, the hypoxic milieu of leiomyoma may contribute to fibroid development and growth. Notably, common treatments for fibroids such as GnRH agonists and uterine artery embolization (UAE) are shown to work at least partly via anti-angiogenic mechanisms. Angiogenic growth factors play an important role in mechanisms of fibroid pathophysiology, including abnormal vasculature and fibroid growth and survival. Moreover, the fibroid's abnormal vasculature together with its aberrant hypoxic and angiogenic response may make it especially vulnerable to disruption of its vascular supply, a feature which could be exploited for treatment. Further experimental studies are required in order to gain a better understanding of the growth factors that are involved in normal and pathological myometrial angiogenesis, and to assess the potential of anti-angiogenic treatment strategies for uterine fibroids.

21 April 2004 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
WCWilliam H. Catherino
William H. Catherino
PLPhyllis C. Leppert
Phyllis C. Leppert
MSMatthew H. Stenmark
Matthew H. Stenmark
MPMark Payson
Mark Payson
CPClariss Potlog‐Nahari
Clariss Potlog‐Nahari
JSJames Hugh Segars
James Hugh Segars

24 April 2018 in Journal of Assisted Reproduction and Genetics
Verified
Journal Article
Closed access
PDF file
JSJaimin S. Shah
Jaimin S. Shah
RSReem Sabouni
Reem Sabouni
KVKamaria C. Cayton Vaught
Kamaria C. Cayton Vaught
COCarter M. Owen
Carter M. Owen
DADavid F. Albertini
David F. Albertini
JSJames Hugh Segars
James Hugh Segars